If you are taking a weight loss medication such as Ozempic, Wegovy, or Zepbound for obesity or other health concerns, you may ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for ...

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (NYSE: LLY) stock is off to the races! This morning, the ...

Liraglutide Offers Long-Term Stability and Expands Hydreight’s Comprehensive GLP-1 Weight Management PortfolioVANCOUVER, British Columbia and LAS VEGAS, April 15, 2025 (GLOBE NEWSWIRE) -- Hydreight ...